Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial

Chest

Volumn 154, Issue 3, 2018, Pages 491-500

  Silvestri, Gerard A ^a   Tanner, Nichole T ^a,b   Kearney, Paul ^c   Vachani, Anil ^d   Massion, Pierre P ^e   Porter, Alexander ^c   Springmeyer, Steven C ^c   Fang, Kenneth C ^c   Midthun, David ^f   Mazzone, Peter J ^g  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c Integrated Diagnostics   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f MAYO CLINIC   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

biomarker; diagnosis; lung cancer; proteomics; pulmonary nodules; risk models

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEIN C163A; PROTEIN LG3BP; UNCLASSIFIED DRUG; TUMOR PROTEIN;

AGED; AREA UNDER THE CURVE; ARTICLE; BENIGN LUNG NODULE; CLASSIFIER; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INVASIVE PROCEDURE; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MALIGNANT LUNG NODULE; MULTICENTER STUDY; MULTIPLE REACTION MONITORING; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROTEOMICS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; ADULT; BLOOD; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; LUNG TUMOR; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLE PULMONARY NODULES; PATHOLOGY; PROCEDURES;

ADULT; AGED; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLE PULMONARY NODULES; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEOMICS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 85048343187     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2018.02.012     Document Type: Article

References (24)

1. Gould, M.K., Tang, T., Liu, I.L., et al. Recent trends in the identification of incidental pulmonary nodules. Am J Respir Crit Care Med 192:10 (2015), 1208–1214.
2. National Lung Screening Trial Research Trial, Aberle, D.R., Adams, A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:5 (2011), 395–409.
3. Gould, M.K., Donington, J., Lynch, W.R., et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:suppl 5 (2013), e93S–120S.
4. Tanner, N.T., Aggarwal, J., Gould, M.K., et al. Management of pulmonary nodules by community pulmonologists: a multicenter observational study. Chest 148:6 (2015), 1405–1414.
5. Tanner, N.T., Porter, A., Gould, M.K., Li, X.J., Vachani, A., Silvestri, G.A., Physician assessment of pretest probability of malignancy and adherence with guidelines for pulmonary nodule evaluation. Chest 152:2 (2017), 263–270.
6. Li, X.J., Hayward, C., Fong, P.Y., et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Translation Med, 5(207), 2013, 207ra142.
7. Vachani, A., Hammoud, Z., Springmeyer, S., et al. Clinical utility of a plasma protein classifier for indeterminate lung nodules. Lung 193:6 (2015), 1023–1027.
8. Grassadonia, A., Tinari, N., Iurisci, I., et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 19:7-9 (2002), 551–556.
9. Yang, L., Wang, F., Wang, L., et al. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. Oncotarget 6:12 (2015), 10592–10603.
10. Moestrup, S.K., Moller, H.J., CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 36:5 (2004), 347–354.
11. Kearney, P., Hunsucker, S.W., Li, X.J., Porter, A., Springmeyer, S., Mazzone, P., An integrated risk predictor for pulmonary nodules. PLoS One, 12(5), 2017, e0177635.
12. Silvestri, G.A., Vachani, A., Whitney, D., et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 373:3 (2015), 243–251.
13. Fagerland, M.W., Lydersen, S., Laake, P., The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional. BMC Med Res Methodol, 13, 2013, 91.
14. Swensen, S.J., Silverstein, M.D., Ilstrup, D.M., Schleck, C.D., Edell, E.S., The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 157:8 (1997), 849–855.
15. Gould, M.K., Ananth, L., Barnett, P.G., Veterans Affairs SNAP Cooperative Study Group. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest 131:2 (2007), 383–388.
16. Schultz, E.M., Silvestri, G.A., Gould, M.K., Variation in experts’ beliefs about lung cancer growth, progression, and prognosis. J Thorac Oncol 3:4 (2008), 422–426.
17. Deppen, S.A., Blume, J.D., Kensinger, C.D., et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA 312:12 (2014), 1227–1236.
18. Wiener, R.S., Wiener, D.C., Gould, M.K., Risks of transthoracic needle biopsy: how high?. Clin Pulm Med 20:1 (2013), 29–35.
19. Ost, D.E., Ernst, A., Lei, X., et al. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions. Results of the AQuIRE registry. Am J Respir Critic Care Med 193:1 (2016), 68–77.
20. Wang Memoli, J.S., Nietert, P.J., Silvestri, G.A., Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest 142:2 (2012), 385–393.
21. Lokhandwala, T., Bittoni, M.A., Dann, R.A., et al. Costs of diagnostic assessment for lung cancer: a Medicare claims analysis. Clin Lung Cancer 18:1 (2017), e27–e34.
22. Vachani, A., Tanner, N.T., Aggarwal, J., et al. Factors that influence physician decision making for indeterminate pulmonary nodules. Ann Am Thorac Soc 11:10 (2014), 1586–1591.
23. Wiener, R.S., Gould, M.K., Slatore, C.G., Fincke, B.G., Schwartz, L.M., Woloshin, S., Resource use and guideline concordance in evaluation of pulmonary nodules for cancer: too much and too little care. JAMA Intern Med 174:6 (2014), 871–880.
24. Mazzone, P.J., Sears, C.R., Arenberg, D.A., et al. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society policy statement. Am J Respir Crit Care Med 196:7 (2017), e15–e29.